NHS sues Reckitt for £89m over Gaviscon supply
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Health Secretary Andrew Lansley and the National Health Service are suing the consumer-goods group Reckitt Benckiser for £89m over the supply of Gaviscon, the company's heartburn medicine.
The case comes after Reckitt was fined £10.2m by the Office of Fair Trading (OFT) in October for admitting abuse of its dominant position in the supply of Gaviscon. The company admitted infringing British and European competition law by withdrawing its profitable Gaviscon Original Liquid from the National Health Service's prescription list after its patent expired in 2005. The move meant that prescriptions would be issued for Gaviscon Advance Liquid, which was protected by patent.
"Vigorous competition between firms supplying the public sector is vital to ensure taxpayers get the best value for money," the OFT's chief executive, John Fingleton, said when the fine was announced last year.
When contacted, Reckitt declined to comment on the Health Secretary's case.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments